Literature DB >> 16102965

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

Mark W Embrey1, John S Wai, Timothy W Funk, Carl F Homnick, Debbie S Perlow, Steven D Young, Joseph P Vacca, Daria J Hazuda, Peter J Felock, Kara A Stillmock, Marc V Witmer, Gregory Moyer, William A Schleif, Lori J Gabryelski, Lixia Jin, I-Wu Chen, Joan D Ellis, Bradley K Wong, Jiunn H Lin, Yvonne M Leonard, Nancy N Tsou, Linghang Zhuang.   

Abstract

Introduction of a 5,6-dihydrouracil functionality in the 5-position of N-(4-fluorobenzyl)-8-hydroxy-[1,6]naphthyridine-7-carboxamide 1 led to a series of highly active HIV-1 integrase inhibitors. These compounds displayed low nanomolar activity in inhibiting both the strand transfer process of HIV-1 integrase and viral replication in cells. Compound 11 is a 150-fold more potent antiviral agent than 1, with a CIC(95) of 40 nM in the presence of human serum. It displays good pharmacokinetics when dosed in rats and dogs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16102965     DOI: 10.1016/j.bmcl.2005.06.105

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

1.  Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.

Authors:  S Kehlenbeck; U Betz; A Birkmann; B Fast; A H Göller; K Henninger; T Lowinger; D Marrero; A Paessens; D Paulsen; V Pevzner; R Schohe-Loop; H Tsujishita; R Welker; J Kreuter; H Rübsamen-Waigmann; F Dittmer
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Retroviral integrase: Structure, mechanism, and inhibition.

Authors:  Dario Oliveira Passos; Min Li; Robert Craigie; Dmitry Lyumkis
Journal:  Enzymes       Date:  2021-08-23

3.  Synthesis and Characterization of Dihydrouracil Analogs Utilizing Biginelli Hybrids.

Authors:  Syed Nasir Abbas Bukhari; Hasan Ejaz; Mervat A Elsherif; Nenad Janković
Journal:  Molecules       Date:  2022-05-04       Impact factor: 4.927

4.  Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase.

Authors:  Richard E Myers; Deenan Pillay
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

5.  Defining the DNA substrate binding sites on HIV-1 integrase.

Authors:  James Dolan; Aiping Chen; Irene T Weber; Robert W Harrison; Jonathan Leis
Journal:  J Mol Biol       Date:  2008-11-07       Impact factor: 5.469

6.  Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

Authors:  Charlotte Charpentier; Laurence Weiss
Journal:  Infect Drug Resist       Date:  2010-10-13       Impact factor: 4.003

7.  8-Hydroxy-1,6-naphthyridine-7-carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.

Authors:  Eunkyung Jung; Ryuichi Majima; Tiffany C Edwards; Ruben Soto-Acosta; Robert J Geraghty; Zhengqiang Wang
Journal:  ChemMedChem       Date:  2022-08-10       Impact factor: 3.540

8.  Raltegravir in the management of HIV-infected patients.

Authors:  Hans-Jürgen Stellbrink
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

9.  Raltegravir: first in class HIV integrase inhibitor.

Authors:  Zelalem Temesgen; Dawd S Siraj
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

Review 10.  Other inhibitors of viral enzymes and functions.

Authors:  H Zimmermann; G Hewlett; H Rübsamen-Waigmann
Journal:  Handb Exp Pharmacol       Date:  2009
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.